2019——2020年上海地区儿童幽门螺杆菌感染及其耐药性分析

doi:10.3969/j.isn.1673-6184.2021.02.003

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (533 KB) HTML ()
Export: BibTeX | EndNote (RIS)

Abstract Abstract: Objective To analyze the resistance of Helicobacter pylori (H. pylori) in children in Shanghai from 2019 to 2020 to four commonly used antibacterial drugs, and provide a basis for the clinical eradication of H. pylori and rational use of antibacterial drugs. Method From January 2019 to October 2020, 1605 children who came to the Children's Hospital of Fudan University in Shanghai and received gastroscopy and rapid urease test were collected. Gastric mucosal membrane samples were collected for H. pylori isolation, culture and identification. E -test method was used for in vitro susceptibility test. Children were divided into 4 groups according to gender and age [1-3 years old (preschool stage), 4-6 years old (kindergarten stage), 7-12 (primary school stage), 13-17 (middle school stage)]. We analyzed the isolation rate of H. pylori, the overall drug resistance rate to metronidazole, clarithromycin, levofloxacin, and amoxicillin and the double/multi-drug resistance. Results A total of 506 H. pylori strains were isolated from the samples of 1605 children enrolled in this study, the isolation rate was 31.6%. There was no gender difference in H. pylori isolation rate (χ2=0.00, P=0.99) and no age difference (χ2=3.945)(P=0.267). The resistance rates of the isolated H. pylori clinical strains to metronidazole, clarithromycin, levofloxacin, and amoxicillin were 42.3%, 25.1%, 8.1%, and 3%, respectively. H. pylori isolated from male and female children were resistant to 4 drugs There was no statistical difference in the rate (χ2=1.042, p=0.307; χ2=0.04, p=0.841; χ2=0.411, p=0.521; χ2=0.623, p=0.430). There was no significant difference in the resistance rates of H. pylori to amoxicillin, levofloxacin and metronidazole (respectively χ2=2.506, P=0.474; χ2= 1.532, P= 0.675; χ2= 2.854, P= 0.46), The resistance rate of H. pylori to clarithromycin in children aged 13-16 years (31.2%) was significantly higher than that in children aged 1 - 3 years (13.3%) (P=0.040). In addition, the resistance rate of clarithromycin + metronidazole was 18%, which was significantly higher than that of clarithromycin + levofloxacin (5.1%), metronidazole + levofloxacin (4.9%), metronidazole + amoxicillin (1.4%) ), amoxicillin + levofloxacin (0.8%) (χ2=172.706, P<0.01). Multi-drug resistance analysis showed that resistance rate of Levofloxacin + clarithromycin + metronidazole was 3.0% , significantly higher than levofloxacin + amoxicillin + clarithromycin (0.6%), amoxicillin + metronidazole + levofloxacin (0.6%) (Χ2=13.907, P=0.01), the H. pylori isolated from another 2 cases were fully resistant to 4 kinds of antibacterial drugs. Conclusion The H. pylori isolated from children in Shanghai from 2019 to 2020 is highly resistant to metronidazole and clarithromycin, and has a low resistance to amoxicillin and levofloxacin. The dual resistance to metronidazole and clarithromycin is relatively high.

Received: 13 January 2021 Published: 01 January 2021

ZTFEL:

R446.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://jmi.fudan.edu.cn/EN/10.3969/j.isn.1673-6184.2021.02.003 OR http://jmi.fudan.edu.cn/EN/Y2021/V16/I2/88

	参考文献
[1]	Hooi J, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017. 153(2): 420-429.
[2]	Aguilera Matos I, Diaz Oliva SE, Escobedo AA, Villa Jiménez OM, Velazco Villaurrutia Y. Helicobacter pylori infection in children. BMJ Paediatr Open. 2020. 4(1): e000679.
[3]	Franceschi F, Tortora A, Gasbarrini G, Gasbarrini A. Helicobacter pylori and extragastric diseases. Helicobacter. 2014. 19 Suppl 1: 52-8.
[4]	de Korwin JD, Ianiro G, Gibiino G, Gasbarrini A. Helicobacter pylori infection and extragastric diseases in 2017. Helicobacter. 2017. 22 Suppl 1.
[5]	Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Review: Extragastric diseases and Helicobacter pylori. Helicobacter. 2020. 25 Suppl 1: e12741.
[6]	The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2021. http://www.eucast.org .
[7]	邱佳琳, 赵青. 幽门螺杆菌菌株类型与儿童胃、十二指肠疾病的关系. 中国医师杂志. 2020. (5): 773-775.
[8]	Dror G, Muhsen K. Helicobacter pylori Infection and Children's Growth: An Overview. J Pediatr Gastroenterol Nutr. 2016. 62(6): e48-59.
[9]	Yin YN, Wang CL, Liu XW, et al. Gastric and duodenum microflora analysis after long-term Helicobacter pylori infection in Mongolian Gerbils. Helicobacter. 2011. 16(5): 389-97.
[10]	姜琳琳. 幽门螺杆菌(Hp)感染与口腔疾病的关系研究. 临床医药文献电子杂志. 2018. (40): 128,138.
[11]	高杰, 林倩云, 彭文玲, 何肖龙, 曹虹. 幽门螺杆菌和胃微生态系统与胃疾病的关系. 中华消化杂志. 2017. (3): 205-208.
[12]	Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002. 347(15): 1175-86.
[13]	Shu X, Yin G, Liu M, Peng K, Zhao H, Jiang M. Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China. Helicobacter. 2018. 23(3): e12481.
[14]	Huang J, Zhou Y, Huang Y, Zhang Y, Yan WL. [Prevalence of Helicobacter pylori infection among children aged 7 to 18 years old: a school-based cross-sectional study in Minhang district of Shanghai in 2014]. Zhonghua Er Ke Za Zhi. 2016. 54(7): 496-9.
[15]	Flores-Trevi?o S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018. 12(8): 819-827.
[16]	张双红, 谢勇, 李弼民等. 儿童幽门螺杆菌毒力基因与抗生素耐药相关性研究. 临床儿科杂志. 2017. (1): 59-63.
[17]	李东丹, 官德秀, 郭景等. 儿童幽门螺杆菌耐药情况及影响因素分析. 中华实用儿科临床杂志. 2019. (19): 1450-1453.
[18]	周颖, 王玉环, 芦军萍, 叶孜清, 黄瑛. 上海市单中心儿童幽门螺杆菌不同治疗方案根除率及其耐药率的横断面调查. 中国循证儿科杂志. 2019. (2): 81-86.
[19]	Li L, Ke Y, Yu C, et al. Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter retrospective study over 7 years. Helicobacter. 2017. 22(3).
[20]	Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci. 2000. 45(1): 68-76.
[21]	秦丹. 儿童幽门螺杆菌抗生素耐药性和毒力基因相关性的研究. 贵阳医学院,译. 见:朱莉, 陈晓霞,主编. 儿科学. ,2015.
[22]	al MPFC. European Helicobacter and Microbiota Study Group and
	Consensus panel． Management of Helicobacter pylori
	infection-the Maastricht Ⅴ/Florence Consensus Ｒeport. 66（1）,2017.
[23]	Pandya HB, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. Indian J Med Microbiol. 2014. 32(4): 408-13.
[24]	宫幼喆. 86例患儿幽门螺杆菌感染情况及其耐药性. 中国微生态学杂志. 2020. (8): 908-911.
[25]	李梦迪, 郑松柏. 幽门螺杆菌耐药的流行病学研究现状. 胃肠病学. 2019. (1): 47-50.
[26]	付盼, 何磊燕, 王爱敏, 宋建明, 薛建昌, 王传清. 2012至2014年上海地区儿童幽门螺杆菌感染及其耐药性分析. 检验医学. 2016. (10): 858-862.
[27]	Mu?oz-Gómez P, Jordán-Castro JA, Abanades-Tercero M, Blanco-González JJ, Andrés Esteban EM, Valle-Mu?oz J. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter. 2018. 23(1).
[28]	张双红. 幽门螺杆菌毒力基因型与儿童胃十二指肠疾病关系以及毒力基因对根除治疗的影响. 南昌大学,译. 见:朱萱,主编. 内科学(消化). ,2016.
[29]	曹喜红. 幽门螺杆菌对克拉霉素耐药性检测的研究进展. 医疗装备. 2020. (6): 197-198.